AU2019345320B2 - Methods of treating cancer - Google Patents

Methods of treating cancer

Info

Publication number
AU2019345320B2
AU2019345320B2 AU2019345320A AU2019345320A AU2019345320B2 AU 2019345320 B2 AU2019345320 B2 AU 2019345320B2 AU 2019345320 A AU2019345320 A AU 2019345320A AU 2019345320 A AU2019345320 A AU 2019345320A AU 2019345320 B2 AU2019345320 B2 AU 2019345320B2
Authority
AU
Australia
Prior art keywords
compound
formula
therapeutically effective
effective amount
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019345320A
Other languages
English (en)
Other versions
AU2019345320A1 (en
Inventor
Alison A. ARMOUR
Richard Messmann
Mike Sathekge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of AU2019345320A1 publication Critical patent/AU2019345320A1/en
Application granted granted Critical
Publication of AU2019345320B2 publication Critical patent/AU2019345320B2/en
Priority to AU2026201845A priority Critical patent/AU2026201845A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2019345320A 2018-09-21 2019-09-20 Methods of treating cancer Active AU2019345320B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201845A AU2026201845A1 (en) 2018-09-21 2026-03-11 Methods of treating cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734649P 2018-09-21 2018-09-21
US62/734,649 2018-09-21
PCT/US2019/052161 WO2020061458A1 (en) 2018-09-21 2019-09-20 Methods of treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201845A Division AU2026201845A1 (en) 2018-09-21 2026-03-11 Methods of treating cancer

Publications (2)

Publication Number Publication Date
AU2019345320A1 AU2019345320A1 (en) 2021-04-22
AU2019345320B2 true AU2019345320B2 (en) 2025-12-11

Family

ID=69887889

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019345320A Active AU2019345320B2 (en) 2018-09-21 2019-09-20 Methods of treating cancer
AU2026201845A Pending AU2026201845A1 (en) 2018-09-21 2026-03-11 Methods of treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201845A Pending AU2026201845A1 (en) 2018-09-21 2026-03-11 Methods of treating cancer

Country Status (9)

Country Link
US (1) US20220125957A1 (enExample)
EP (1) EP3852816A4 (enExample)
JP (2) JP2022501441A (enExample)
KR (1) KR20210095620A (enExample)
CN (4) CN121338051A (enExample)
AU (2) AU2019345320B2 (enExample)
CA (1) CA3112806A1 (enExample)
IL (2) IL281600B2 (enExample)
WO (1) WO2020061458A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
JP2023539990A (ja) 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド 放射性薬剤および方法
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160228587A1 (en) * 2013-10-18 2016-08-11 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
EP3400229B1 (en) * 2016-01-10 2024-03-06 Provincial Health Services Authority 18/19f-labelled compounds which target the prostate specific membrane antigen
DK3498308T3 (da) * 2017-12-13 2025-01-02 Sciencons AS Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160228587A1 (en) * 2013-10-18 2016-08-11 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRATOCHWIL CLEMENS ET AL: THE JOURNAL OF NUCLEAR MEDICINE, vol. 57, no. 8, 16 March 2016 (2016-03-16), US, pages 1170 - 1176, XP055926259, ISSN: 0161-5505, *
SATHEKGE MIKE ET AL: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 46, no. 1, 19 September 2018 (2018-09-19), pages 129 - 138, *

Also Published As

Publication number Publication date
IL323981A (en) 2025-12-01
CN121338051A (zh) 2026-01-16
CN121154858A (zh) 2025-12-19
EP3852816A1 (en) 2021-07-28
CN113164631A (zh) 2021-07-23
IL281600A (en) 2021-05-31
KR20210095620A (ko) 2021-08-02
AU2026201845A1 (en) 2026-04-02
EP3852816A4 (en) 2022-07-13
CA3112806A1 (en) 2020-03-26
WO2020061458A1 (en) 2020-03-26
US20220125957A1 (en) 2022-04-28
IL281600B2 (en) 2026-03-01
JP2022501441A (ja) 2022-01-06
IL281600B1 (en) 2025-11-01
JP2024178159A (ja) 2024-12-24
CN121130116A (zh) 2025-12-16
AU2019345320A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
US20250235466A1 (en) Methods of treating cancer
IL323981A (en) Methods of treating cancer
JP7748438B2 (ja) シールド剤およびそれらの使用
CN109053616A (zh) 前列腺特异性膜抗原（psma）的标记的抑制剂及其用途
US20180036364A1 (en) Methods of treating cancer with a psma ligand-tubulysin compound
RU2811406C2 (ru) Способы лечения рака
RU2825637C2 (ru) Способы лечения рака
HK40047004A (en) Methods of treating cancer
WO2017205447A1 (en) Methods of treating cancer with a psma ligand-tubulysin compound

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)